Diffuse follicle center lymphoma, intrapelvic lymph nodes
ICD-10 C82.56 is a billable code used to indicate a diagnosis of diffuse follicle center lymphoma, intrapelvic lymph nodes.
Diffuse follicle center lymphoma (DFCL) is a subtype of non-Hodgkin lymphoma characterized by the proliferation of neoplastic B-cells within the follicle center of lymphoid tissue. This specific code, C82.56, indicates that the lymphoma is primarily located in the intrapelvic lymph nodes, which can include nodes in the iliac and pelvic regions. Patients may present with symptoms such as lymphadenopathy, abdominal discomfort, or systemic B-symptoms, which include fever, night sweats, and weight loss. The diagnosis is typically confirmed through histopathological examination of lymph node biopsies, and immunophenotyping is often utilized to distinguish DFCL from other lymphomas. Staging of the disease is crucial for determining prognosis and treatment options, with the Ann Arbor staging system commonly employed. Treatment protocols may include chemotherapy, immunotherapy, or radiation therapy, depending on the stage and overall health of the patient. Regular follow-up is essential to monitor for disease progression or recurrence.
Comprehensive documentation of diagnosis, staging, treatment plans, and follow-up care.
Diagnosis and management of patients presenting with lymphadenopathy and B-symptoms.
Ensure accurate coding of treatment modalities and any complications arising from therapy.
Detailed reports on biopsy findings, including immunophenotyping results.
Evaluation of lymph node biopsies for suspected lymphoma.
Pathology reports must clearly indicate the subtype of lymphoma for accurate coding.
Used when a biopsy is performed to confirm the diagnosis of diffuse follicle center lymphoma.
Pathology report must include details of the biopsy and immunophenotyping.
Pathologists should ensure accurate reporting of lymphoma subtype.
Common treatments include chemotherapy, immunotherapy, and radiation therapy, depending on the stage of the disease and the patient's overall health.
